NASDAQ · SPRB
Healthcare · Biotechnology
$40.40
Up+$0.83 (+2.05%)
Updated Oct 20, 2026, 11:29 PM
SID Score
2.7/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · SPRB
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 19, 2026
SPRB closed at $40.40 after 21 trading sessions, down 24.77% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 19, 2026 | $39.97 | $41.00 | $39.2475 | $40.40 | 57.1K |
| Oct 16, 2026 | $41.53 | $41.84 | $39.21 | $39.65 | 88.43K |
| Oct 15, 2026 | $39.00 | $41.88 | $39.00 | $41.47 | 63.78K |
| Oct 14, 2026 | $40.00 | $41.44 | $38.06 | $38.98 | 113.39K |
| Oct 13, 2026 | $42.80 | $42.91 | $40.19 | $40.35 | 110.8K |
| Oct 12, 2026 | $44.09 | $44.935 | $42.55 | $42.87 | 74.87K |
| Oct 9, 2026 | $44.84 | $45.04 | $42.80 | $44.05 | 83.76K |
| Oct 8, 2026 | $43.50 | $45.645 | $43.34 | $45.54 | 50.82K |
| Oct 7, 2026 | $42.56 | $45.3999 | $42.37 | $44.40 | 59.7K |
| Oct 6, 2026 | $45.60 | $46.72 | $42.50 | $42.785 | 101.89K |
| Oct 5, 2026 | $45.51 | $46.7955 | $43.83 | $45.42 | 65.09K |
| Oct 2, 2026 | $46.58 | $47.725 | $44.125 | $45.71 | 77.24K |
| Oct 1, 2026 | $48.15 | $49.20 | $44.47 | $44.77 | 79.63K |
| Sep 30, 2026 | $47.78 | $49.95 | $47.76 | $48.58 | 61.26K |
| Sep 29, 2026 | $47.55 | $47.9999 | $46.55 | $47.27 | 84.21K |
| Sep 28, 2026 | $48.28 | $48.99 | $47.01 | $47.51 | 42.37K |
| Sep 25, 2026 | $49.22 | $49.31 | $47.54 | $48.72 | 37.19K |
| Sep 24, 2026 | $49.01 | $49.50 | $47.58 | $49.02 | 85.78K |
| Sep 23, 2026 | $50.50 | $50.735 | $45.01 | $49.415 | 174.77K |
| Sep 22, 2026 | $54.05 | $54.98 | $49.23 | $49.99 | 140.92K |
| Sep 21, 2026 | $53.84 | $55.055 | $53.07 | $53.70 | 97.02K |
The latest Smart Investors Daily articles mentioning SPRB.
Company
Market Activity
Research & News
SPRB research
Company profile and research snapshot.
Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with unmet medical needs. The pipeline products of the company include Tralesinidase Alfa (TA-ERT), and Tildacerfont/ Cortibon, a Companion Diagnostic, developed in partnership with HMNC Brain Health.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 24, 2026 | Citizens | Market Outperform | — |
| Sep 17, 2026 | Lake Street | Buy | — |
| Aug 17, 2026 | Guggenheim | Buy | — |
| Aug 13, 2026 | Citizens | Market Outperform | — |
| Jul 13, 2026 | B. Riley Securities | Buy | — |
No generated briefing is available yet.
Benzinga · Mar 10, 2026
Citizens analyst Jonathan Wolleben maintains Spruce Biosciences (NASDAQ:SPRB) with a Market Outperform and lowers the price target from $180 to $170.
Benzinga · Mar 10, 2026
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Spruce Biosciences (NASDAQ:SPRB) with a Buy and maintains $200 price target.
Benzinga · Mar 9, 2026
Benzinga · Mar 9, 2026
SPRUCE BIOSCIENCES INC by Spruce Biosciences, Inc. (OTC:SPRB) reported quarterly losses of $(36.25) per share which missed the analyst consensus estimate of $(4.22) by 757.99 percent. This is a 15.2 percent increase over
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning SPRB.
